EVKEEZA 150 MG — DIN 02541769
EVINACUMAB : 150 MG · ULTRAGENYX PHARMACEUTICAL INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is EVKEEZA?
EVKEEZA 150 MG contains EVINACUMAB : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02541769, held by ULTRAGENYX PHARMACEUTICAL INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 21-Nov-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EVKEEZA used for?
Adjunct to diet and other LDL-C lowering therapies for the treatment of adult and pediatric patients 6 months and older with homozygous familial hypercholesterolemia (HoFH).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Evinacumab cost around the world?
Evinacumab is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Italy publishes a ex-factory (classe H); Romania publishes a max producer price; Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Italy | ex-factory (classe H) | 1 | 1 | EUR███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
3 pack listings across 3 brand entries and 3 price bases, refreshed 03 Sep 2026. Ranges span every Evinacumab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 345 mg/2.3 mL (150 mg/mL) and 1,200 mg/8 mL (150 mg/mL) single-use vials. |
| Storage | Store at 2°C to 8°C. If refrigerated, allow to come to room temperature (up to 25°C) prior to administration. Administer immediately once prepared. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Evinacumab |
|---|---|
| ATC code | C10AX17 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02541769 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2541769 |
| Brand name | EVKEEZA |
| Generic / active ingredient | EVINACUMAB : 150 MG |
| Market authorization holder | ULTRAGENYX PHARMACEUTICAL INC |
| Health Canada schedule | Prescription |
| ATC code | C10AX17 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10AX |
| Current status | MARKETED |
| Status date | 21-Nov-2023 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
15 mg/kg administered by intravenous (IV) infusion over 60 minutes every 4 weeks. Administered by a health professional only. Rate may be slowed or interrupted if adverse reactions occur.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation.
Warnings and precautions
Hypersensitivity reactions including anaphylaxis and infusion reactions reported. Potential for fetal harm; determine pregnancy status before initiation.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC C10AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ezetimibe | ACH-EZETIMIBE · ACT EZETIMIBE · AG-EZETIMIBE · APO-EZETIMIBE · +19 more | 26 | 18 | Yes |
| Alirocumab | PRALUENT | 5 | 3 | Yes |
| Lomitapide | JUXTAPID | 3 | 3 | Yes |
| Omega-3-Triglycerides Incl. Other Esters And Acids | FLEX 500 · HERBALIFELINE · OMEGA-3 · VASCEPA | 4 | 1 | Yes |
| Evolocumab | REPATHA | 2 | 1 | Yes |
| Inclisiran | LEQVIO | 1 | 1 | Yes |
| Evinacumab | EVKEEZA | 1 | 1 | Yes |
| Dextrothyroxine | CHOLOXIN - TAB 4MG · CHOLOXIN TAB 2MG · CHOLOXIN TABLET 4MG | 4 | 0 | Not in Canada |
| Omega-3-Triglycerides, Combinations | OMEGA-3 FACTORS WITH VITAMIN E | 1 | 0 | Not in Canada |
| Probucol | LORELCO | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C10AA | Atorvastatin · Cerivastatin · Fluvastatin · Lovastatin · Pravastatin · +2 more | 759 | 286 |
| C10AB | Bezafibrate · Clofibrate · Fenofibrate · Gemfibrozil | 87 | 13 |
| C10AC | Colesevelam · Colestipol · Colestyramine | 29 | 6 |
| C10AD | Nicotinic Acid | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.